Repeated peripheral administration of adult mesenchymal stem cells has a positive impact on Abeta amyloid pathology in a transgenic mouse model of Alzheimer’s disease

Alzheimer’s disease (AD) is a neurodegenerative disorder pathologically characterized by extracellular senile plaques, primarily composed of polymerized amyloid-beta (Abeta) peptides. There is currently no cure for this disease that represents one of today’s major healthcare challenges due to its severe socio-economic burden. The huge potential offered by adult ischemic-tolerant mesenchymal stem cells (itMSC) for the treatment of AD and other neurodegenerative disorders is still not fully exploited.